Hemochromatosis and Ferroportin Disease (Type 4 Hemochromatosis)

Hemochromatosis and Ferroportin Disease (Type 4 Hemochromatosis)

Hemochromatosis is a group of hereditary disorders characterized by excessive absorption and accumulation of iron. The body absorbs more iron from food and water than it needs, and because humans have no effective physiological mechanism for actively excreting excess iron, the surplus gradually accumulates in tissues and organs.

Over time, this iron overload can cause progressive damage to multiple organ systems, particularly the liver, heart, pancreas, joints, skin, and endocrine glands. If left untreated, iron deposition may result in cirrhosis, diabetes mellitus, cardiomyopathy, hormonal disorders, arthritis, and other serious complications.

---

Normal Iron Regulation

Iron balance is tightly controlled by the hormone hepcidin, which is produced by the liver. Hepcidin regulates the activity of ferroportin, the body's primary iron-export protein found on intestinal cells, macrophages, hepatocytes, and placental cells.

Under normal circumstances:

• Ferroportin exports iron from cells into the bloodstream.
• Hepcidin binds to ferroportin when iron stores are sufficient and causes it to be removed from the cell surface.
• This process reduces iron absorption and prevents excessive iron accumulation.

Disruption of the hepcidin–ferroportin pathway is the underlying mechanism in several forms of hereditary hemochromatosis.

---

Types of Hereditary Hemochromatosis

Several genetic forms of hemochromatosis have been identified:

Type 1 (HFE-Related Hemochromatosis)

The most common form is caused by mutations in the HFE gene, particularly:

• C282Y
• H63D

These mutations impair normal hepcidin regulation, leading to excessive intestinal iron absorption. Iron gradually accumulates throughout the body, often becoming clinically apparent in adulthood.

Type 2 (Juvenile Hemochromatosis)

A rare and severe form caused by mutations in:

• HJV (hemojuvelin)
• HAMP (hepcidin)

Iron overload develops rapidly, often before age 30, and may result in severe cardiac and endocrine complications.

Type 3 Hemochromatosis

Caused by mutations in the TFR2 gene, resulting in impaired iron sensing and regulation.

Type 4 Hemochromatosis (Ferroportin Disease)

A rare form caused by mutations in the SLC40A1 gene, which encodes the ferroportin protein.

Unlike most other forms of hereditary hemochromatosis, Ferroportin Disease is inherited in an autosomal dominant manner, meaning a mutation in only one copy of the gene is sufficient to cause disease.

---

Ferroportin Disease (Type 4 Hemochromatosis)

Ferroportin Disease is unique because the clinical presentation depends on the specific mutation affecting ferroportin function.

Two major phenotypes have been recognized:

Type 4A (Classical Ferroportin Disease / Loss-of-Function)

In Type 4A disease, ferroportin loses its ability to export iron effectively.

As a result:

• Iron becomes trapped within macrophages.
• Iron accumulates primarily in the liver, spleen, and bone marrow.
• Serum ferritin levels are markedly elevated.
• Transferrin saturation is usually normal or low.
• Circulating iron levels may remain relatively normal.

Because iron is sequestered within macrophages rather than freely circulating, organ damage tends to be less severe than in classic hemochromatosis. However, some individuals may still develop liver fibrosis or cirrhosis later in life.

Key Features of Type 4A

• High ferritin
• Normal or low transferrin saturation
• Iron accumulation within macrophages
• Mild to moderate clinical course
• Increased risk of anemia during treatment

Treatment must be approached cautiously because excessive phlebotomy can produce symptomatic anemia.

---

Type 4B (Hepcidin-Resistant Ferroportin Disease / Gain-of-Function)

In Type 4B disease, ferroportin remains active despite normal hepcidin signaling.

The mutated transporter becomes resistant to hepcidin, leaving the "iron export gate" permanently open.

Consequently:

• Excessive iron enters the bloodstream.
• Transferrin saturation becomes elevated.
• Iron accumulates directly within parenchymal organs.
• The pattern resembles classic HFE-associated hemochromatosis.

Key Features of Type 4B

• High ferritin
• High transferrin saturation
• Progressive iron accumulation in organs
• Increased risk of liver, cardiac, endocrine, and pancreatic injury
• Often responsive to standard phlebotomy treatment

---

Iron Storage and Laboratory Findings

The body's primary iron-storage protein is ferritin, which safely stores iron inside cells and releases it when needed.

Serum ferritin generally reflects total body iron stores. Elevated ferritin is therefore an important marker of iron overload.

However, ferritin is also an acute-phase reactant and may be elevated due to:

• Infection
• Inflammation
• Chronic liver disease
• Malignancy
• Metabolic syndrome

For this reason, ferritin should always be interpreted alongside additional iron studies.

Important Laboratory Tests

Test	Significance

Test Significance Serum Ferritin         Estimates total body iron stores Transferrin Saturation (TSAT)         Measures circulating iron burden Serum Iron         Amount of iron in blood Total Iron-Binding Capacity (TIBC)         Reflects transferrin availability Genetic Testing         Identifies causative mutations MRI Iron Quantification         Measures iron accumulation in organs

A transferrin saturation greater than 45% is generally considered suggestive of iron overload and warrants further evaluation.

Clinical Manifestations Symptoms often develop gradually and may remain nonspecific for years. Early Symptoms Fatigue Weakness Joint pain Abdominal discomfort Reduced exercise tolerance Loss of libido Advanced Manifestations Liver Iron accumulation in the liver may cause: Hepatomegaly Elevated liver enzymes Fibrosis Cirrhosis Liver failure Increased risk of hepatocellular carcinoma Pancreas Pancreatic iron deposition can damage insulin-producing beta cells, leading to: Impaired glucose tolerance Diabetes mellitus Historically, the combination of diabetes and skin pigmentation was referred to as "bronze diabetes." Heart Cardiac iron overload may result in: Cardiomyopathy Arrhythmias Conduction abnormalities Heart failure Joints Iron deposition may cause: Arthralgia Arthritis Stiffness and chronic pain The second and third metacarpophalangeal joints of the hands are commonly affected. kin Excess iron and melanin deposition can cause: Hyperpigmentation Bronze or gray skin discoloration Endocrine System Iron can accumulate in endocrine glands, particularly the pituitary gland (hypophysis), leading to hormonal dysfunction. Potential consequences include: Hypogonadotropic hypogonadism Reduced testosterone production Infertility Erectile dysfunction Menstrual irregularities Thyroid dysfunction Adrenal dysfunction Growth hormone abnormalities These endocrine disorders are complications of iron overload rather than separate diseases. Neurological and Behavioral Effects Neurological symptoms are relatively uncommon but may include: Dizziness Syncope (fainting) Cognitive changes Seizures in rare cases Some patients report: Irritability Mood changes Increased aggression However, these are not considered classic diagnostic features of hemochromatosis. Diagnosis Diagnosis relies on a combination of clinical evaluation, laboratory studies, imaging, and genetic testing. Initial Evaluation Serum ferritin Transferrin saturation Liver function tests Complete blood count Confirmatory Testing Genetic testing for HFE mutations and other hereditary forms SLC40A1 testing when Ferroportin Disease is suspected MRI assessment of liver and cardiac iron concentration Liver biopsy in selected cases where diagnosis or staging remains uncertain Treatment and Management Treatment aims to reduce iron stores before irreversible organ damage occurs. Therapeutic Phlebotomy Therapeutic phlebotomy is the first-line treatment for most forms of iron overload. Regular blood removal: Eliminates iron-containing red blood cells Forces the body to mobilize stored iron Gradually lowers ferritin levels Treatment is typically divided into: Induction Phase Frequent phlebotomy until target ferritin levels are achieved. Maintenance Phase Periodic phlebotomy to prevent reaccumulation of iron. Target ferritin levels are often maintained between 50 and 100 ng/mL, although treatment goals may vary by patient. Ferroportin Disease Considerations Type 4A Because iron is trapped within macrophages: Patients may tolerate phlebotomy poorly. Aggressive treatment can cause anemia. Lower-volume or less frequent phlebotomy may be necessary. Type 4B Management generally resembles classic hemochromatosis: Regular phlebotomy is usually effective. Iron overload can often be controlled successfully if identified early. Iron Chelation Therapy When phlebotomy is not possible, such as in patients with: Significant anemia Poor venous access Certain cardiac conditions Iron chelation medications may be used to remove excess iron. Examples include: Deferoxamine Deferasirox Deferiprone Prognosis When diagnosed and treated early, hereditary hemochromatosis is one of the most manageable genetic metabolic disorders. Early intervention can: Prevent cirrhosis Reduce the risk of diabetes Protect cardiac function Minimize endocrine complications Preserve normal life expectancy Once advanced fibrosis, cirrhosis, or severe organ damage has developed, some complications may be irreversible, making early detection especially important. Summary Hemochromatosis is a hereditary disorder of iron metabolism characterized by excessive iron absorption and progressive iron accumulation in tissues. The most common form is HFE-associated (Type 1) hemochromatosis, but several other genetic variants exist, including Ferroportin Disease (Type 4) caused by mutations in the SLC40A1 gene. Ferroportin Disease is unique because it occurs in two distinct forms. Type 4A results from loss of ferroportin function, causing iron trapping within macrophages and elevated ferritin with normal or low transferrin saturation. Type 4B results from hepcidin-resistant ferroportin, producing elevated ferritin, high transferrin saturation, and organ iron overload resembling classic hemochromatosis. Diagnosis relies on ferritin, transferrin saturation, imaging, and genetic testing. Treatment is primarily therapeutic phlebotomy, although management must be individualized, especially in Type 4A disease. With timely diagnosis and appropriate treatment, most patients can avoid major complications and maintain a normal life expectancy Scientific and Medical References  These references include peer-reviewed journal articles, government health agency resources, and clinical guidelines used by medical professionals worldwide.

Ferroportin Disease https://rarediseases.org/rare-diseases/ferroportin-disease/ Hemochromatosis type 4 https://rarediseases.info.nih.gov/diseases/10094/hemochromatosis-type-4 Type 4 haemochromatosis (ferroportin disease) https://www.haemochromatosis.org.uk/type-4-haemochromatosis-ferroportin-disease Hemochromatosis, Type 4 (HFE4) https://www.malacards.org/card/hemochromatosis_type_4_2 Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment https://www.gastrojournal.org/article/S0016-5085(10)00872-3/fulltext?referrer=https%3A%2F%2Fchatgpt.com%2F Hemochromatosis https://www.niddk.nih.gov/health-information/liver-disease/hemochromatosis Platelet transfusion: Current challenges Plaquettes et transfusions plaquettaires : défis d’aujourd’hui et de demain https://www.sciencedirect.com/science/article/abs/pii/S1246782018300612?via%3Dihub Hepcidin and iron homeostasis https://www.sciencedirect.com/science/article/pii/S016748891200016X?via%3Dihub Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases https://journals.lww.com/hep/fulltext/2011/07000/diagnosis_and_management_of_hemochromatosis__2011.36.aspx
© 2000-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742